It is currently Wed Aug 27, 2014 10:19 pm

News News of Gilenya

Site map of Gilenya » Forum : Gilenya

Gilenya, or Fingolimod, is the first approved oral disease modifying drug for MS.

Scottish decision due on oral MS drug Gilenya

Image

The Scottish Medicines Consortium (SMC) will decide on today if it will recommend the prescribing of the first oral pill for the treatment of Multiple Sclerosis in Scotland.

Currently, suffers face painful daily injections deep into the muscle or having to travel to hospital for infusion therapy to try to control the disease, which damages the central nervous system, causing a range of disabilities such as problems with co-ordination, speech and vision.

But this ...
Read more : Scottish decision due on oral MS drug Gilenya | Views : 1067 | Replies : 0


Deaths hit oral MS drug, Gilenya

Image


Novartis AG's Gilenya multiple sclerosis pill lost market share for the first time in January, following the deaths of some patients soon after taking the first pill available for the disease in the United States.

Gilenya's share of the U.S. market for so-called immunomodulatory drugs against MS fell to 6.1 percent from 6.2 percent in December, according to data from Wolters Kluwer NV, a market research company. The decline was the first after 15 ...
Read more : Deaths hit oral MS drug, Gilenya | Views : 1771 | Replies : 0


Safety of oral MS pill Gilenya reviewed after deaths

Image

Health Canada is reviewing a new multiple sclerosis drug that has been linked to 11 deaths.

There have been no reports of deaths in Canada of people taking the Novartis drug, which is sold under the brand name Gilenya.

Health Canada says that of the deaths outside the country, it's not clear whether the drug itself caused them, or whether other factors played a role.

Both the U.S. Food and Drug Administration and the ...
Read more : Safety of oral MS pill Gilenya reviewed after deaths | Views : 1520 | Replies : 0


A randomized, controlled trial of fingolimod in Japanese MS

A randomized, controlled trial of fingolimod (FTY720) in Japanese MS patients

Image


Abstract
Background: Fingolimod (FTY720) has previously shown clinical efficacy in phase II/III studies of predominantly Caucasian populations with multiple sclerosis (MS).

Objectives: To report six-month efficacy and safety outcomes in Japanese patients with relapsing MS treated with fingolimod.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1309
Read more : A randomized, controlled trial of fingolimod in Japanese MS | Views : 1597 | Replies : 0


EU says MS drug Gilenya needs heart monitoring

Image

The European Medicines Agency advised doctors to continuously monitor patients for six hours after giving them a first dose of Novartis AG's multiple sclerosis drug Gilenya, casting a shadow over the potential blockbuster product.

The move came as the organisation started a review into the safety of the medicine, following reports of heart problems in patients and the death of one person in the United States within 24 hours of starting treatment.

The Swiss ...
Read more : EU says MS drug Gilenya needs heart monitoring | Views : 1468 | Replies : 1


Oral MS drug Gilenya reviewed by EU after 11 patient deaths

Image

The European Medicines Agency started a review of Novartis AG’s Gilenya pill for multiple sclerosis after 11 deaths among patients who received treatment.

The reports raise concern that the drug, the first oral medicine for the debilitating neurological disease, may harm the heart, the London-based agency said in an e-mailed statement today. Eric Althoff, a spokesman for Novartis in Basel, Switzerland, didn’t immediately return a call and e-mail requesting comment.

Novartis said last month ...
Read more : Oral MS drug Gilenya reviewed by EU after 11 patient deaths | Views : 1535 | Replies : 0


Death of MS patient prompts FDA Gilenya review

Image

The death of a multiple sclerosis patient shortly after a first dose of fingolimod (Gilenya) is under review by the FDA, the agency said.

No specific cause of death has been determined in the case, which occurred on Nov. 23, and the FDA emphasized that it had not ascertained that the drug was related to the fatal outcome.

Fingolimod's prescribing information includes a warning about bradycardia and/or atrioventricular conduction block in the first hours ...
Read more : Death of MS patient prompts FDA Gilenya review | Views : 1779 | Replies : 1


Gilenya® shows positive clinical outcomes in new trial

Image


Novartis announced today new data from the Phase III 2309 study showing patients with relapsing-remitting multiple sclerosis (RRMS) treated with Gilenya® (fingolimod) had a statistically significant 48% reduction in annualized relapse rates (ARR) at 24 months compared to placebo. Study 2309 is the third Phase III clinical trial to demonstrate a significant reduction of relapse rates with Gilenya treatment in patients with RRMS.

The two previous Gilenya studies involved a two-year, placebo-controlled trial and ...
Read more : Gilenya® shows positive clinical outcomes in new trial | Views : 841 | Replies : 0


Novartis investigating death possibly linked to Gilenya

Image

One year after Novartis won FDA approval for a new type of drug to treat relapsing forms of multiple sclerosis and delay the progression of physical disabilities, the drugmaker is now investigating a death tied to its pill, which is called Gilenya. The disclosure, which was made by a Wall Street analyst, has the potential to cast a pall over a drug that has been expected to generate blockbuster sales.

Specifically, this is the ...
Read more : Novartis investigating death possibly linked to Gilenya | Views : 1259 | Replies : 0


Anger at NICE oral MS drug Gilenya decision

Image

Campaigners have condemned a decision that could lead to a ban on the use of the first pill to treat multiple sclerosis.

The National Institute of Health and Clinical Excellence (NICE) ruled the drug was too expensive following a second consultation on its use.

It says it is not minded to make it available on the NHS but a final decision has not been made yet and people can still make their views known. ...
Read more : Anger at NICE oral MS drug Gilenya decision | Views : 1285 | Replies : 0


 

Login  •  Register


Statistics

Total posts 219532 • Total topics 22659 • Total members 14279


Contact us | Terms of Service